moneyheap
BBIO · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is BridgeBio Pharma, Inc. Common Stock (BBIO) stock moving?
BBIO has risen from $68.12 on Oct 22 to $78.67 on Nov 10, about 15%, with the sharpest gains after Q3 results on Oct 29. Revenue of $353.2M beat the $285.5M estimate and the per-share loss narrowed to $0.42 against $0.58 expected, though $75.0M of the revenue was a one-time Bayer milestone. Underlying Attruby net product revenue of $253.2M rose about $31M sequentially. Volume spiked to 4.9M and 5.8M shares on Oct 29 and 30, versus roughly 2-3M on normal days, and Nov 10 closed near its session high of $79.83 on 3.3M shares. Analysts stayed constructive after results: Morgan Stanley (Overweight, $88), TD Cowen (Buy, $100 from $110) and Canaccord (Buy, $108). The stock trades below the lower end of the targets, but the Nov 4-5 pullback from $77.89 to $74.27 shows the rally can reverse quickly. The main near-term event is the BBP-418 PDUFA date of Nov 27, 2026 under Priority Review, followed by oral infigratinib (Feb 4, 2027) and encaleret (May 8, 2027). The company reported $1.5B in cash, which funds these launches. Recent news flow is mostly routine, such as awards, conference appearances and employee grants.
News behind the analysis
- BridgeBio Reports Third Quarter 2026 Financial Results and Corporate UpdatesQ3 revenue reached $353.2M, including $253.2M of U.S. Attruby net product revenue and a one-time $75.0M Bayer milestone. Cash and securities stood at $1.5B as of Sep 30.
- BridgeBio Pharma Q3 EPS $(0.42) Beats $(0.58) Estimate, Sales $353.171M Beat $285.497M EstimateBenzinga reported that the Q3 per-share loss of $0.42 beat the $0.58 consensus, and revenue of $353.2M beat the $285.5M estimate.
- BridgeBio Pharma Reports Third Quarter 2026 Financial ResultsQuarterly results were released with revenue of $353.2M and a per-share loss of $0.42.
- Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88Morgan Stanley kept its Overweight rating and raised its price target to $88 from $87.
- TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100TD Cowen kept its Buy rating but cut its price target to $100 from $110.
- UBS Reports Unanticipated Near-Term Tailwinds for BridgeBio's AttrubyUBS analysts identified unexpected near-term tailwinds for Attruby (acoramidis), the FDA-approved heart disorder drug.
- Canaccord Genuity Raises BridgeBio Pharma Price Target to $108Canaccord Genuity maintained its Buy rating and raised its price target to $108 from $106.
- BridgeBio Pharma Announces Upcoming Poster Presentations at AHA Scientific Sessions 2026BridgeBio will present five posters on acoramidis and ATTR-CM at the American Heart Association Scientific Sessions 2026.
- BridgeBio Pharma Announces Equity Inducement Grants for New EmployeesRestricted stock units were approved for 80 new employees under Nasdaq listing rule 5635(c)(4).
- BridgeBio Pharma Announces Participation in Upcoming Healthcare Investor ConferencesManagement will hold fireside chats at four healthcare investor conferences in November and December 2026.
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a commercial-stage biotech company that develops medicines for genetic diseases. Its main product is Attruby (acoramidis), a drug for a heart disease called ATTR cardiomyopathy, and it has several late-stage drugs waiting on FDA decisions, including encaleret (for ADH1), BBP-418 (for the muscle disease LGMD2I/R9) and infigratinib (for achondroplasia).
How it makes money
Most of its revenue comes from US sales of Attruby. In Q2 2026 Attruby brought in about $222M of roughly $244M in total revenue. It also earns royalties on acoramidis, which partners sell as Beyonttra in Europe and Japan, plus licensing and milestone payments. Revenue was about $353M in Q3 2026, and trailing 12-month revenue was roughly $0.95B. The company still loses money and has funded itself with stock sales, debt, royalty deals and a roughly $1B preferred equity raise in July 2026.
What usually moves BBIO
- Attruby prescription growth and competition in ATTR-CM
- FDA decisions on its late-stage drugs
- Clinical trial results
- Cash burn, financing and dilution
- Drug pricing and reimbursement policy